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Received 21 December 2009; received in revised form 21 February 2010; accepted 25 February 2010Abstract Induced pluripotent stem cells (iPSCs) hold great promise for regenerative medicine. For the application of
iPSCs to forms of autologous cell therapy, suitable animal models are required. Among species that could potentially be used for
this purpose, nonhuman primates are particularly important, and among these the marmoset offers significant advantages.
In order to demonstrate the feasibility of the application of iPSC technology to this species, here we derived lines of marmoset
iPSCs. Using retroviral transduction with human Oct4, Sox2, Klf4 and c-Myc, we derived clones that fulfil critical criteria
for successful reprogramming: they exhibit typical iPSC morphology; they are alkaline phosphatase positive; they express high
levels of NANOG, OCT4 and SOX2 mRNAs, while the corresponding vector genes are silenced; they are immunoreactive for
Oct4, TRA-1-81 and SSEA-4; and when implanted into immunodeficient mice they produce teratomas that have derivatives of all
three germ layers (endoderm, α-fetoprotein; ectoderm, βIII-tubulin; mesoderm, smooth muscle actin). Starting with a
population of 4×105 newborn marmoset skin fibroblasts, we obtained ∼100 colonies with iPSC-like morphology. Of these, 30
were expanded sufficiently to be cryopreserved, and, of those, 8 were characterized in more detail. These experiments provide
proof of principle that iPSC technology can be adapted for use in the marmoset, as a future model of autologous cell therapy.
© 2010 Elsevier B.V. All rights reserved.Introduction
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doi:10.1016/j.scr.2010.02.0032006), human (Takahashi et al., 2007), rhesus monkey (Liu
et al., 2008), rat (Liao et al., 2009), pig (Ezashi et al., 2009),
and dog (Shimada et al., 2009). It is widely thought that an
important future use for iPSC technology is a form of
autologous cell therapy in which the donor of the repro-
grammed somatic cells is also the recipient of the cells
following appropriate differentiation protocols (Yamanaka,
2007). Potentially, any mammalian species could serve as a
translational model for this form of autologous cell therapy,
but nonhuman primates are particularly suited for such
studies because of the aspects of their anatomy and
physiology that they share with humans. Among nonhuman
primates, the marmoset is especially relevant for biomedical
research because of well developed models in this species for.
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Huntington's disease), stroke, and spinal cord injury;
reproductive biology, infectious disease, and behavioral
research; and drug development and safety assessment
(Mansfield, 2003). Forms of experimental cell therapy have
been developed for models of neural injury in the marmoset
(Virley et al., 1999; Oka et al., 2004) and the marmoset has
been proposed as an ideal model for elucidation of safety and
efficiency of new technologies in regenerative medicine
(Tomioka and Sasaki, 2008).
Marmoset embryonic stem cells were originally derived
by Thomson (Thomson et al., 1996); more recently, 4 other
marmoset ESC lines were reported (Sasaki et al., 2005;
Muller et al., 2009). While ESCs have vast potential for
future cell therapy and regenerative medicine, iPSCs have
the specific advantages that (1) it is widely believed that
derivatives of iPSCs could be transplanted back into the
original donor from which the cells were derived without
immune rejection; and (2) iPSCs can potentially be
derived from a wide variety of donor individuals of
differing ages, health status and genetic background.
Here we report the creation of induced pluripotent stem
cells from the marmoset, as a first step toward experi-
mental cell therapy based on use of autologous iPSCs in
this species.
Materials and MethodsGrowth of marmoset skin fibroblasts and retroviral
infection
Marmoset fibroblasts were prepared from newborn skin by
digestion with 5 mg/ml collagenase type I (Sigma) over-
night. They were cultured in Dulbecco's Modified Eagle's
Medium (DMEM) supplemented with 10% Cosmic Calf Serum
(HyClone Laboratories, Logan, UT), 0.1 mg/ml penicillin
and 0.05 mg/ml gentamicin. Retroviral plasmids (pMXs)
containing human cDNAs for Oct4, Sox2, Klf4 and c-Myc
(Takahashi et al., 2007) were obtained from Addgene Inc..
Virus was prepared in Plat-A cells and was used for
coinfection of marmoset fibroblasts as previously de-
scribed (Wu et al., 2009).
Because the marmoset and human reprogramming
factors are highly homologous, we used vectors encoding
the human reprogramming factors. The marmoset proteins
encoded by OCT4, SOX2 and KLF4 cDNAs are highly similar
to the human proteins. The marmoset and human OCT4,
SOX2, and KLF4 proteins are 98.3%, 99.7% and 99.4%
identical by amino acid sequence, while the domains of
the proteins thought to be critical for their activity as
transcription factors are 99.3%, 100% and 100% identical,
respectively.
Conditions for reprogramming and iPSC
colony isolation
Marmoset fibroblasts were trypsinized and plated in Matri-
gel-coated 6-well plates. The day following plating, cells
were infected with the mixture of four retroviruses (Wu
et al., 2009); the infection was repeated two more times at24 hour intervals. Following infection, cells were maintained
in DMEM with 10% Cosmic Calf Serum and 1 mM valproic acid
(Huangfu et al., 2008). Cells were grown under these
conditions for 12 days. Cells were then trypsinized and
replated at a 1:2 ratio on Matrigel-coated 35-mm dishes in
medium without valproic acid. After a further 7 days,
colonies with iPSC morphology were identified and were
isolated using Accutase (Bajpai et al., 2008; Li et al., 2009).
This enzymatic isolation was designated as passage 1.
Following removal from the fibroblast culture, colonies
were replated in knockout DMEM with 20% knockout serum
replacement (KSR, Invitrogen) and 20 ng/ml bFGF onto
mitomycin C-treated mouse embryonic fibroblasts (MEFs,
GlobalStem Inc., Rockville, MD).Growth of iPSC clones
After cells were grown on MEFs for two passages, they were
removed from the dish with Accutase; and were then
transferred to feeder-free culture conditions, comprising
Matrigel-coated culture plates, and a medium consisting of
45% knockout DMEM, 20% ES-qualified fetal bovine serum
(GlobalStem), 35% medium conditioned by 24 hour incuba-
tion with mitomycin C-treated mouse embryonic fibroblasts
(medium comprising knockout DMEM with 20% KSR), 0.1 mM
β-mercaptoethanol, nonessential amino acids, 10 μM ROCK
inhibitor Y-27632 (Li et al., 2009) and 20 ng/ml bFGF. Cells
were passaged continuously under these conditions, using
Accutase, at a 1:3 split ratio. For assessment of alkaline
phosphatase activity, cultures were fixed in 4% paraformal-
dehyde and were incubated with substrate according to the
manufacturer's instructions (SigmaFAST BCIP/NBT kit). Kar-
yotyping was performed using conventional techniques by
Cell Line Genetics, Madison, WI.qPCR for pluripotency markers
RNAwas prepared frommarmoset iPSC clones andwas used for
qPCR. As a control, we prepared RNA from the human
embryonic stem cell line I6 (Amit and Itskovitz-Eldor, 2002).
Primers were designed to amplify marmoset NANOG, OCT4
(POU5F1), and SOX2. Primers were selected to fulfil two
criteria: (a) they were 100% complementary to both the
marmoset and human sequences for these cDNAs; and (b) there
was at least one marmoset-specific and one human-specific
restriction enzyme site within the amplified sequence. qPCR
was performed using SYBR green in an ABI 7900HT instrument.Immunocytochemistry for pluripotency markers
Cells were fixed in 4% paraformaldehyde andwere processed for
fluorescence immunocytochemistry. Antibodies used were:
Oct4; (mouse monoclonal, SC-5279, Santa Cruz Biotechnology,
at 1:100); TRA-1-81 (phycoerythrin-conjugated mouse mono-
clonal, 09-0012, Stemgent, at 1:50); SSEA-4 (mousemonoclonal
SP2/0, University of Iowa Developmental Hybridoma Bank, at
1:100). Images were obtained using a Zeiss Axiovert fluores-
cence microscope.
182 Y. Wu et al.Teratoma formation and immunohistochemistry for
differentiation markers
For assessment of differentiation potential, marmoset iPSCs
were implanted into immunodeficient mice. We used a
highly immunodeficient mouse model (RAG2-/-, γc-/-).
Initially we injected cells in the subrenal capsule based on
our previous studies on cancer cell growth in this immuno-
deficient model and transplant site (Sun et al., 2004). This is
also a site often employed for teratoma formation (Przy-
borski, 2005; Prokhorova et al., 2008; Hentze et al., 2009).
Using a transrenal injection, 2×106 cells were introduced per
animal and mice were sacrificed at 6 weeks following
transplantation. Subsequently we also used subcutaneous
injection of the same number of cells suspended in 100 μl of
50% Matrigel in culture medium (Prokhorova et al., 2008;
Hentze et al., 2009); mice were sacrificed after 8 weeks.
Tumors were excised, fixed in 4% paraformaldehyde, and
processed for conventional histology.
Sections were stained with hematoxylin and eosin or were
used for immunohistochemical detection of markers of
differentiation of the three germ layers. Following antigen
retrieval (0.1 M citrate buffer, 105 °C, 20 minutes) sections
were incubated at 4 °C overnight with the following
antibodies: (ectodermal) βIII-tubulin (chicken polyclonal,
AB9354, Chemicon, at 1:500); (endodermal) α-fetoprotein
(rabbit polyclonal, A0008, Dako, at 1:100); (mesodermal)
smooth muscle actin (mouse monoclonal 1A4 at 1:50).
Antibody localization was developed using biotinylated
secondary antibodies and the Vectastain Elite ABC kit (VectorFigure 1 Reprogramming marmoset skin fibroblasts. Primary cultu
retroviruses encoding Oct4, Sox2, Klf4 and c-Myc and treated with v
morphology developing among the transduced fibroblasts, 21 days aft
of altered morphology stained for alkaline phosphatase activity. (B)
morphology. (C) Alkaline phosphatase staining of cells in three adjac
of putative iPSC colonies following isolation. D and E shows a colon
feeder layers (D and E, photographs obtained 2 days apart). F showLaboratories, Burlingame, CA). Sections were lightly coun-
terstained with hematoxylin.Results
Reprogramming of marmoset skin fibroblasts to
iPSCs
Following the infection of marmoset skin fibroblasts with
retroviruses encoding Oct4, Sox2, Klf4 and c-Myc, cultures
were maintained in normal fibroblast growth conditions with
the addition of valproic acid (Huangfu et al., 2008). After 14-
21 days, small colonies of altered morphology were noted in
the confluent fibroblast cultures. These colonies comprised
small rapidly dividing cells with high nuclear/cytoplasmic
ratio and prominent nucleoli (Takahashi et al., 2007). When
cultures containing such colonies were fixed and stained for
alkaline phosphatase activity, most of the small colonies of
altered morphology were found to be positive for alkaline
phosphatase (Fig. 1), a marker of pluripotency (O'Connor
et al., 2008). These colonies expanded rapidly, producing
very dense patches of small cells (Fig. 1). These cells have
the morphological characteristics previously reported for
human iPSCs (Takahashi et al., 2007).
Starting with a population of 4×105 marmoset fibroblasts,
we obtained ∼100 colonies of cells with iPSC-like morphol-
ogy. Colonies were isolated and expanded on MEF feeder
layers (Fig. 1). Of those colonies that were isolated from the
fibroblast cultures, 30 showed sustained growth and wereres of newborn marmoset skin fibroblasts were transduced with
alproic acid as described in the text. (A - C) Colonies of altered
er retroviral infection. (A) Low power image of multiple colonies
Phase-contrast appearance of a single colony with altered cell
ent colonies developing among the fibroblasts. (D - F) Expansion
y similar to those in A - C following isolation and growth on MEF
s a similar colony after assay for alkaline phosphatase activity.
Figure 2 Karyotypes of marmoset iPSC clones. Metaphase chromosomes of two clones (#15 and #88) were analyzed by conventional
G banding.
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cryopreserved. Of these, 8 were selected for further study.
Karyotypes were studied at an early passage (passage 4). The
karyotypes of 3 clones (#15, #88, and #B8) were investigatedFigure 3 Growth of isolated marmoset iPSC clones. Following isola
free conditions as described in the text. Observations were performe
show two different clones photographed at intervals of one day (A cl
growth of the cells and the patterns of growth of cells under feeder-f
clone (B8) that have been fixed at low, middle and high cell density (
alkaline phosphase staining within the cultures as cells achieve highby G banding and were found to be normal. Karyotypes for 2
of these clones are shown in Figure 2.
Following the initial expansion of marmoset iPSC clones on
MEF feeder layers, we investigated if the cells could be growntion of putative iPSC clones, cells were expanded under feeder-
d at passages 6 - 8. The series of phase-contrast images in A and B
one #15; B clone #88). The two series of images show the rate of
ree conditions. C shows alkaline phosphatase activity of cells of a
2 day intervals: C, C' and C'') showing the pattern of expansion of
cell density.
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coated dishes inmediumcontaining 20% fetal bovine serumand
35% MEF-conditioned medium and continued to grow rapidly
(Fig. 3). After plating in feeder-free conditions, cells were
observed in dense patches with more sparse cells intervening.
Dense patches expanded, filling the culture dishes (Fig. 3).
When cultureswere fixed and stained for alkaline phosphatase,
we observed that the dense patches of small rapidly dividing
cellswere strongly alkaline phosphatasepositive,while the flat
cells among the patches were weakly positive or negative
(Fig. 3). The positive dense patches shown in Figure 3 have the
same morphology as the colony shown at higher power in
Figure 1F. The 8 clones that were selected for detailed studies
have been grown continuously in culture without evidence of
any reduction in their growth rate for N20 passages in each
case. Over this period they maintained the patterns of growth
and alkaline phosphatase activity shown in Figure 3.
Markers of pluripotency in marmoset iPSCs
Marmoset iPSC clones expressed pluripotency markers at
levels that were comparable to that in a human embryonicFigure 4 Markers of pluripotency in marmoset iPSC clones. Levels
compared to the levels in a human embryonic stem cell line, I6,
reprogramming. qPCR was performed on RNA isolated from triplicate
shown for each clone. The level in the I6 cells is indicated by a dashed
shown for each clone. Vector RNA levels were determined using ve
primers that amplify both endogenous and vector sequences (see Mastem cell line (I6) or exceeded that level (Fig. 4). In all
8 marmoset iPSC clones, NANOG and SOX2 mRNA levels were
higher than those in I6 cells, and levels of OCT4 were
comparable to that of I6 cells. Levels of OCT4 mRNA were
N100-fold higher in iPSC clones than in the fibroblasts used
for reprogramming, and levels of NANOG and SOX2 were N50-
fold higher (Fig. 4). We assessed the relative levels of vector
and total mRNAs for OCT4 and SOX2, two of the factors used
for reprogramming. We used primer pairs specific for
reprogramming vectors (vector sequence 5′ primer and
coding region 3′ primer). Vector OCT4 mRNA was present
at 0.01% to 0.1% of that of total OCT4 mRNA, while vector
SOX2 mRNA was present at 0.1% to 1% of the total SOX2
mRNA. In addition, the PCR products amplified by the
primers for endogenous OCT4 and SOX2mRNAs were digested
almost completely by restriction enzymes specific for the
marmoset sequence (see Materials and Methods). We
conclude that endogenous OCT4 and SOX2 mRNAs comprise
99% of the totals. Additionally, using fluorescence immuno-
cytochemistry, we found nuclear Oct4 in most cells within
marmoset iPSC cultures, with a greater intensity in the dense
patches of cells that have typical iPSC morphology and areof mRNA for NANOG, OCT4 (POU5F1) and SOX2 in 8 clones were
and to levels in the marmoset skin fibroblasts (MF) used for
cultures at early passage levels (6 - 8). The relative level ± S.E. is
line. Below, ratios of total/vector mRNA for OCT4 and SOX2 are
ctor-specific primers; total mRNA levels were determined using
terials and Methods).
185Marmoset induced pluripotent stem cellsalkaline phosphatase positive (Fig. 5). Similarly, two plasma
membrane markers of pluripotency, TRA-1-81 and SSEA-4
(Takahashi et al., 2007), were also detected in the denser
patches (Fig. 5).Differentiation of marmoset iPSC clones to cells of
the three germ layers
In order to assess the potential of marmoset iPSC clones to
differentiate to cells of all three germ layers, cells were
transplanted into immunodeficient mice. Because previous
studies showed that the subrenal capsule site is an excellent
one for teratoma development (Przyborski, 2005; Prokhor-
ova et al., 2008; Hentze et al., 2009) we first injected cells
beneath the kidney capsule by transrenal injection. Subse-
quently we also tested teratoma formation by subcutaneous
injection in 50% Matrigel (Prokhorova et al., 2008; Hentze et
al., 2009). Teratomas developed in both the subrenal capsule
and subcutaneous sites. Immunohistochemical studies
revealed that tissue structures within the teratomas repre-
sented derivatives of all three germ layers (Fig. 6). Ectoder-
mal tissue (developing neural tissue) was demonstrated by
presence of βIII-tubulin; mesodermal tissue by smooth
muscle actin; and endodermal tissue by α-fetoprotein. The
structures stained by the anti-α-fetoprotein antibody re-
sembled the structures previously identified by this marker
in teratomas (Zhang et al., 2009). Because it has beenFigure 5 Markers of pluripotency in marmoset iPSC clones. Fluores
pluripotency on fixed cells of three clones. A, Oct4 (clone #81); B, Treported that teratomas derived from incompletely repro-
grammed cells formed tissues of ectodermal and mesoder-
mal origin but not of endodermal origin (Chan et al., 2009)
we performed histological studies of the development of
mature structures of endodermal origin. Teratomas from
marmoset iPSCs contained a variety of mature endodermal
tissues, including simple columnar and pseudostratified
epithelia, epithelia with goblet cells, and exocrine glandular
structures (Fig. 7).Discussion
The development of technology to generate induced
pluripotent stem cells from potentially any somatic cell has
provided an invaluable tool for cell therapy and regenerative
medicine. The creation of patient-specific iPSCs by repro-
gramming of somatic cells would create an inexhaustible
source of cells that could be used to derive differentiated
cells required for patient-specific therapy, such as cardio-
myocytes, neurons, and pancreatic beta cells (Yamanaka,
2007). In order to provide the appropriate translational proof
of principle that differentiated cells derived from individual-
specific iPSCs will be safe and effective, and will not be
subject to rejection by the immune system, appropriate
studies are needed in suitable mammalian models. Although
rodents are excellent sources of cells for reprogramming, it
is generally accepted that primates will serve as the mostcence immunocytochemistry was performed for three markers of
RA-1-81 (clone #15); C, SSEA-4 (clone #88).
Figure 6 Teratoma formation by marmoset iPSC clones formed by transplantation in immunodeficient mice in the subrenal capsule
(A, C - E, clone #15; B, clone #81). Hematoxylin/eosin-stained sections are shown in A and B. Immunohistochemical demonstration of
differentiation markers for (C) an endodermal marker (α-fetoprotein); (D) a mesodermal marker (smooth muscle actin); (E) an
ectodermal marker (βIII tubulin). For each antibody, a stained section (C - E) is shown together with an adjacent section stained with
hematoxylin and eosin (C' - E'). Teratomas were formed by transplantation of cells at passages 7 - 8. Size bar=500 μm.
186 Y. Wu et al.appropriate mammalian models for autologous cell therapy
and other aspects of regenerative medicine (Wolf et al.,
2004). Among primates, the marmoset stands out as
especially relevant for biomedical research because of well
developed models in this species for several human disease
states.
Here we produced several lines of iPSCs from newborn
marmoset fibroblasts. While the methodology we used
followed many aspects of those previously used, we also
provided significant modifications of the methodology. It is
generally assumed that feeder-free conditions for iPSC and ES
cell growth offer advantages for subsequent studies of
directed differentiation and cell transplantation. In most
prior reprogramming studies, iPSCs have been developed and
grown on feeder layers. In some cases cells were later adapted
to feeder-free conditions. In the experiments reported here,
we transferredmarmoset iPSCclones to feeder-free conditions
at an early stage. Many clones grew well under these
conditions, were expanded, and were cryopreserved. It has
been noted that under some circumstances the adaptation of
human ES cells to feeder-free conditions of cell lines that havebeen grown routinely on feeders is associated with the
expansion of altered subclones that may have abnormal
karyotypes (Hasegawa et al., 2006). Marmoset iPSCs trans-
ferred to feeder-free conditions exhibited a normal karyotype.
Moreover they maintained a constant pattern of growth, with
expanding patches of small cells with typical iPSC/ES cell
morphology (high nuclear/cytoplasmic ratio and prominent
nucleoli). Cells between patches tended to differentiate, and
were weakly alkaline phosphatase positive or were negative.
As cells achieved high density, patches of iPSCs expanded
while the differentiated cells grew more slowly or not at all;
thus cultures always reached high percentages of undifferen-
tiated cells at high density. These cells also had markers of
pluripotency (nuclear Oct4, and plasma membrane TRA-1-81
and SSEA-4).
A quantitative assessment of the major pluripotency
genes (NANOG, OCT4, SOX2) showed that mRNAs for these
genes were maintained at a level either comparable to
that of the I6 human ESC line (OCT4), or above that level
(NANOG and SOX2) in the case of 8 marmoset iPSC clones
selected for detailed study. Importantly, we showed that
Figure 7 Histological analysis of differentiation within subcutaneous teratomas (marmoset iPSC clone B8; passage 7). Hematoxylin
and eosin stain. A Low power view of subcutaneous teratomas; sections showing teratoma in subdermal tissue. (Bar=2.5 mm). B
Higher power view showing varieties of differentiated tissues. Boxed areas are also shown at high power in C (lower box) and D (upper
box). (Bar=500 μm) C - F High power views of epithelium with goblet cells (C), exocrine glandular structure (D), simple columnar
epithelium (E) and pseudostratified epithelium (F). (Bar=150 μm).
187Marmoset induced pluripotent stem cellsthe levels of vector RNA for OCT4 and SOX2 were at levels
much lower than those of the corresponding endogenous
genes. Recent studies show that reprogramming by viral
vectors is associated with complete silencing of the viral
genome when reprogramming is complete, and that
partially reprogrammed cells still express the viral
genome at a high level (Chan et al., 2009). In the
marmoset iPSCs, viral OCT4 mRNA was present at a level
of only 0.01% to 0.1% of the level of the endogenous gene,
and viral SOX2 mRNA was present at a level of 0.1% to 1% of
the level of the endogenous gene. In contrast, in partially
reprogrammed clones, the viral mRNAs exceed the levels
of the endogenous mRNAs (Chan et al., 2009). Moreover,
the same study showed that teratomas formed by partially
reprogrammed cells lacked differentiated tissues of
endodermal origin, while this was present in teratomas
formed from fully reprogrammed cells. In the teratomas
formed from marmoset iPSCs we found differentiated
endoderm, as evidenced by immunohistochemistry and by
conventional histological analysis, that showed well-
developed features of tissues of endodermal lineage. For
example, goblet cells are characteristic of several
epithelia of endodermal origin. The goblet cells detected
in the marmoset iPSC teratomas closely resemble those of
the small intestine of the marmoset (Miraglia et al., 1967).
We conclude that the marmoset iPSC clones described
here are pluripotent and fully reprogrammed.
While retroviral silencing is a feature of full reprogram-
ming, it is also important for suppressing the potential
adverse consequences of transgene expression, particu-
larly c-Myc (Nakagawa et al., 2008). While retrovirally
generated iPSCs are highly valuable for basic and trans-
lational experiments in animals, for clinical use it is likely
that reprogramming methods will be employed in whichthe reprogramming vectors are excised from the cells
before therapeutic use (Soldner et al., 2009; Chang et al.,
2009) or methods that do not employ genetic modification
at all (Zhou et al., 2009; Kim et al., 2009). Nevertheless,
the relative efficiency of reprogramming using retroviral
vectors makes this method attractive for solving basic
issues. Once these are solved, safer methods can and
should be developed, and compared with methods that use
genetic modification.
The presently reported characterization of iPSCs from
the marmoset provides the proof of principle of iPSC
generation in this species, and paves the way for the
generation of indvidual-specific iPSCs for proof of princi-
ple experiments on autologous cell therapy in nonhuman
primates.Acknowledgments
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